Read the latest positive news, breakthroughs, and inspiring stories about targeted therapy, curated daily by BrightWire.
Scientists have developed breakthrough drugs targeting RAS, a gene mutated in one-third of all cancers that experts once thought was impossible to treat. Decades of research funded by the National Cancer Institute are now saving lives with personalized therapies for pancreatic and other cancers.
Scientists at Berkeley Lab have cracked a major barrier preventing doctors from using one of the most powerful cancer therapies available. Their new technique could bring targeted alpha therapy to hospitals nationwide.
The FDA approved 10 new molecularly targeted cancer therapies in just one year, offering hope to patients with breast, lung, ovarian, prostate, brain, and blood cancers. These precision treatments attack cancer cells while sparing healthy tissue, marking a significant shift in how doctors fight the disease.
Lorie Young's ultra-rare lung cancer mutation qualified her for a targeted therapy clinical trial that's giving hope to patients with genetic abnormalities. Her story reveals how personalized cancer treatment is transforming what's possible for advanced-stage patients.
A groundbreaking new pill has been approved to treat pancreatic cancer, doubling survival time compared to chemotherapy and targeting the mutations found in over 90% of cases. For decades, these mutations were considered impossible to treat.
Thousands of blood cancer patients in England and Wales can now access breakthrough oral treatments that significantly extend survival. The new therapies reduce disease progression by up to 35% compared to standard chemotherapy.
Adults with a rare form of lung cancer now have a new treatment option after their disease stops responding to initial therapies. The FDA just approved zidesamtinib for patients with ROS1-positive lung cancer who've already tried one targeted treatment.
A breakthrough lung cancer treatment targeting a rare genetic mutation just won FDA approval two months ahead of schedule. The drug offers new hope for younger patients, often in their 40s and 50s, whose cancer stopped responding to earlier treatments.
Revolutionary targeted therapies are turning once-deadly thyroid cancers into manageable diseases, giving patients real hope where there was little before. New medical guidelines help doctors navigate these breakthrough treatments that can shrink tumors and reduce invasive surgeries.
A new treatment for a deadly soft-tissue cancer has delivered breakthrough results, extending survival by over eight months compared to placebo. For patients with advanced dedifferentiated liposarcoma, this marks the first effective targeted therapy ever proven in a major trial.
Researchers at IIT BHU discovered a chemical compound that destroys breast cancer cells while leaving healthy tissue untouched, offering hope for treatments without chemotherapy's harsh side effects. The molecule targets two key proteins cancer cells need to survive, essentially starving them and triggering self-destruction.
Ben Whitehead entered remission from a one-of-a-kind lymphoma after targeted therapy starved his cancer cells. The Mount Gambier father went from three months to live to planning his future in just eight months.